We observed a decrease of SOD activity in MS subjects, supporting the notion that antioxidant defense capability was impaired in MS subjects [4], although the alteration of the absolute level of SOD activity seems weak, which could limit the discriminatory performance of the SOD activity in differentiating MS from non-MS. The gene discussed is SOD1; the disease is myeloid sarcoma.